ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Código de la empresaNDRA
Nombre de la empresaENDRA Life Sciences Inc
Fecha de salida a bolsaJun 28, 2017
Fundada en2007
Director ejecutivoMr. Alexander Y. Tokman
Número de empleados21
Tipo de títulosOrdinary Share
Fin del año fiscalJun 28
Dirección3600 Green Ct Ste 350
CiudadANN ARBOR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal48105-2440
Teléfono17343350468
Sitio Webhttps://www.endrainc.com/
Código de la empresaNDRA
Fecha de salida a bolsaJun 28, 2017
Fundada en2007
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

No datos encontrados